Page 28 - Practice Guidelines News Today

Rusfertide met the study's primary endpoint, with a statistically significant higher number of responders on rusfertide versus placebo (p=0.0003)Rusfertide continues to be generally well tolerated with

In a systematic review and meta-analysis, Tao Lin and colleagues investigate the incidence, risk factors and clinical outcomes of HBV reactivation in non-liver solid organ transplant recipients with resolved HBV infection.

Researchers call for better inclusion of people in Africa and with African ancestry in studies on inherited genetics to help address disparities in prostate cancer outcomes.

/PRNewswire/ -- Citing the significant public and economic impact posed by an aging population, increased visual impairments and blindness in the U.S., the...

PXL065 Phase 2 trial for the treatment of NASH met its primary efficacy endpoint for liver fat content reduction at 36-weeks for all doses. Fibrosis improvement by 1 stage without worsening

/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and full year ended December 31, 2022,...

Including M&I Resource of 56,700,000 tonnes grading 10.07% Manganese Toronto, Ontario--(Newsfile Corp. - March 3, 2023) - Canadian Manganese Company Inc. (NEO: CDMN) ("CDMN" or the "Company") is pleased

Find information about available non-chemotherapy treatments for thyroid carcinoma, including total thyroidectomy, radiodine treatment, and ablation.

Annual conference featuring more than a thousand worldwide oncology professionals will present new research findings, latest NCCN Guidelines updates, and best practices achieving quality cancer

/PRNewswire/ -- Today, the National Comprehensive Cancer Network® (NCCN®)—a not-for-profit alliance of leading United States cancer centers—announced a new...